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Letters to the EditorDiagnostic accuracy of FibroScan and comparison to liver
ﬁbrosis biomarkers in chronic viral hepatitis: A
multicenter prospective study (the FIBROSTIC study)This is a reply to the letter to the Editor by Munteanu et al.,
Munteanu et al. have commented on our paper [1] and claim that
our conclusions were ‘‘hazardous’’. We beg to disagree for the fol-
lowing reasons.
(a) According to Munteanu et al., there was a high risk of
selection bias in the FIBROSTIC study because we included
patients who had a liver biopsy either (1) on clinical grounds
only, without considering the results of previous non-invasive
tests or (2) because previous non-invasive tests were abnormal
and/or discordant (see Patients and methods section). However,
the inclusion criteria of our study closely reﬂect the real-life sit-
uation in France where non-invasive tests were widely promoted
and disseminated before being assessed. The French Health
Authorities were calling for an independent, comparative assess-
ment, and this is a reason why they supported our study. In the
prevailing context, it was appropriate to assess the diagnostic
performance of transient elastography (TE) both as a primary
evaluation of liver ﬁbrosis and in a sample of patients with abnor-
mal results in non-invasive tests. Diagnostic accuracy results
were provided for both groups of patients (see Supplemental
material, Appendix 5.4., page 7). It was the same in both groups
for signiﬁcant ﬁbrosis (AUROC 0.766 vs. 0.760, p = 0.83) and
slightly better for the diagnosis of cirrhosis in the patients not
selected on the basis of abnormal non-invasive test results
(AUROC 0.914 vs. 0.864, p = 0.10). Our results thus provided no
evidence of a selection bias.
(b) Citing a method they have developed, Munteanu et al.
state that an AUROC of 0.78 for signiﬁcant ﬁbrosis is ‘‘mathemat-
ically equivalent’’ to an AUROC of 0.90 for cirrhosis. There is to
date no evidence for this mathematical equivalence. All one can
say is that the higher AUROC for cirrhosis reﬂects a well known
feature of diagnostic tests, i.e. their better performance for diag-
nosing more severe conditions [2]. Munteanu et al. also afﬁrm
that we should have used the Obuchowski method [3] to stan-
dardize AUROC measures and prevent a spectrum effect. But
standardization is required only when ‘‘the distribution of ﬁbro-
sis stages in the study sample do not ﬁt the reference distribution
in the population to which the indices are applied’’ (citation from
abstract of Ref. [3]). The problem is that the reference distribution
of ﬁbrosis stages in chronic hepatitis patients in France is not well
known. We had no need to standardize AUROCs because our
study sample was representative due to our choice of inclusion
criteria; the sample was large; the distribution by ﬁbrosis stage
was close to the ‘‘reference’’ distribution used by Poynard et al.
[4]; we compared non-invasive test accuracies in the same study
population.
(c) We acknowledged in the discussion that liver biopsy is
an imperfect reference standard for evaluating ﬁbrosis stage.
Munteanu et al. claim that the ‘‘authors underestimated the risk
of false positives/negatives of a 20 mm biopsy’’ and support this
claim, rather misleadingly, by citing our work (‘‘the risk of error
of a 20 mm liver biopsy is 30% for false negatives/positives using
large surgical samples [5]’’). The 30% error rate we give in Ref. [5]
is the error rate in ﬁbrosis evaluation when using morphometric
analysis and not when using histological scoring (e.g. the META-
VIR system) on a 20 mm liver biopsy. To our knowledge, no
known histological semi-quantitative score of ﬁbrosis takes
account of ﬁbrosis evaluated by morphometry. Liver biopsy
clearly has limitations such as errors related to sampling varia-
tion but it should not be forgotten that the algorithm applied in
the Fibrotest calculation ironically uses ‘‘histological staging of
a set of biopsies as the gold standard’’.
(d) We did not state that the diagnostic accuracy of biomark-
ers and TE in detecting cirrhosis were similar but that the AUR-
OCs of Fibrotest, Apri and Hepascore were signiﬁcantly lower
(p <104, p <104, p = 0.07, respectively) than the AUROC for
Fibroscan (see Table 2).
(e) We agree with Munteanu et al. that the prediction of clin-
ical endpoints may be a better objective than the estimation of
diagnostic accuracy, even when a satisfying reference standard
is available. However, which endpoints we wish to predict using
non-invasive tests merits discussion. Predicting treatment
response may also be a good idea as they suggest in a recently
published paper.
(f) The 2006 guidelines of the French National Authority for
Health (HAS) stated that there was no study available comparing
the efﬁcacy of different approaches of evaluating liver ﬁbrosis
and that the ‘‘STIC’’ study (renamed FIBROSTIC study), ongoing
in 2006, might provide some answers [6]. The FIBROSTIC study
is the largest independent study (none of the authors have any
ﬁnancial conﬂicts of interest) comparing the diagnostic accuracy
of biomarkers, in one and the same population of patients, to that
of Fibroscan. It is not just conﬁrmatory but provides novel infor-
mation, for instance, on the probability of the occurrence of sig-
niﬁcant ﬁbrosis and cirrhosis according to different classes of
value of non-invasive tests results (see Table 3 and Supplemen-
tary data, Appendix 7). Its purpose was to help decision-makers
correctly position these tests within the decision-tree describing
the treatment decision and care of patients with viral chronic
hepatitis.
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Is there any association between HCV multiplication and
iron induced liver injury in chronic hepatitis C?
To the Editor:
We were very interested in the excellent paper by Fillebeen
et al. published in a recent issue of the Journal of Hepatology
[1]. The paper presents unexpected results on the role of iron
in hepatitis C virus (HCV) replication. The authors conﬁrm
the results of a previous publication and show, in in vitro
experiments, the iron-mediated inhibition of HCV replication.
These results are surprising and are not consistent with
those of earlier studies in which iron was implicated in the
upregulation of HCV translation [2,3] or the enhancement of
HCV replication [4]. These results are also intriguing in the
context of clinical observations of patients with chronic hepati-
tis C (CHC). It is rather difﬁcult to determine a simple correla-
tion between the iron-induced inhibition of HCV replication
and the less favourable prognosis of CHC patients with iron
overload [5].
The attempt to apply the results of the experimental models
to clinical situations, according to some selected reports, is
quite risky. Fillebeen et al. cited three previous reports showing
the association of HFE gene mutations, an etiologic agent of
HFE hemochromatosis, with efﬁcacy of antiviral treatment. Per-
haps, they selected these papers because of the possible asso-
ciations between iron concentration, intensity of HCV
multiplication, and viral load, which is a known strong predic-
tor of SVR.
Distante et al. found that C282Y mutations (2 C282Y homo-
zygotes and 31 C282Y heterozygotes) were independent predic-
tors of SVR but this effect was probably caused by a lack of HFE
phenotypic expression and by factors that were associated with
the virus. In their study, carriers of C282Y mutations did not
show any signiﬁcant increase in serum concentrations of ferri-
tin nor increased transferrin saturation compared to patients
with wild type HFE. Moreover, the authors stated that serum
ferritin concentration was predictive of non-response to inter-
feron and ribavirin therapy [6]. Based on our own observations,
two out of 152 CHC patients with iron overload were homozy-
gous for the C282Y mutation and died at the age of 40, with
rapidly progressive liver failure due to liver cirrhosis and hepa-
tocellular carcinoma, after unsuccessful antiviral therapies. Leb-
ray et al. did not conﬁrm that the H63D mutation was a
signiﬁcant predictor of SVR (p = 0.089) [7]. In a large study by
Bonkovsky et al., iron and HFE gene mutations were analysed
in relation to PEG-IFN therapy in advanced CHC patients. A pos-
sible positive inﬂuence of HFE mutations on the effectiveness of
antiviral therapy was found, especially with the H63D muta-
tion, but only in patients without conﬁrmed hereditary hemo-
chromatosis or iron overload based on a liver biopsy.
Moreover, the presence of iron deposits in hepatocytes did
not affect the rate of SVR [8].
In contrast, in our study, we found that treatment failure
was positively correlated with elevated iron serum concentra-
tion and the presence of HFE gene mutations, in 61 out of
152 CHC patients treated with PEG-IFN plus ribavirin. However,
HFE gene mutations did not appear to be the main factor
responsible for iron overload in CHC [9]. In conclusion, addi-
tional experiments on cellular models and clinical studies are
required to elucidate the impact of iron on HCV replication
in terms of the pathogenesis of acute and chronic HCV infec-
tion and to explain the differences between clinical and exper-
imental observations.
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